Loading
The dose for a frail 80-year-old is guessed from what fit 55-year-olds tolerated. Running dose-finding in older patients directly, using frailty assessment, would give doses they can actually take.
Dedicated dose-finding and dose-comparison cohorts in patients aged 75 and over or with frailty on geriatric assessment, run in parallel with or after the main dose-finding, using tolerability, function and QoL alongside efficacy. The GO2 trial in advanced oesophago-gastric cancer showed that reduced-intensity chemotherapy in frail and older patients was non-inferior with better QoL, demonstrating the approach.
Shares GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth, Older and multimorbid patients are excluded and undertreated, Wrong doses, Oesophageal cancer.
Shares GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth, Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
Shares GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth, Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated, Wrong doses.
Shares GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth, Geriatric assessment.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
Shares Older and multimorbid patients are excluded and undertreated, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.